other material
confidence high
sentiment positive
materiality 0.80
Tectonic reports favorable TX2100 Phase 1a safety results and FDA Fast Track for HHT
Tectonic Therapeutic, Inc.
- TX2100 Phase 1a single ascending doses were generally safe and well-tolerated across all six planned cohorts; no deaths, SAEs, or severe TEAEs at any dose.
- FDA granted TX2100 Fast Track designation for hereditary hemorrhagic telangiectasia (HHT) and cleared the IND for a U.S. Phase 1b trial in HHT patients.
- Tectonic plans an open-label Phase 1b trial in hematologic-support dependent HHT by year-end 2026 and a placebo-controlled Phase 2 in moderate-to-severe HHT in early 2027.
- The Phase 1a trial enrolled 48 healthy adults ages 18-55 across six cohorts of eight, randomized 3:1 to TX2100 or placebo; Part B multiple-dose enrollment is complete.
- PK results showed target-mediated drug disposition at low concentrations, supporting once weekly or every other week subcutaneous dosing; detailed data to be presented Oct. 12-16, 2026.